Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms

Tatsuo Okada, Jun Wada, Kazuyuki Hida, Jun Eguchi, Izumi Hashimoto, Masako Baba, Akihiro Yasuhara, Kenichi Shikata, Hirofumi Makino

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Thiazolidinediones are ligands for peroxisome proliferator-activated receptor (PPAR)-γ, widely used as insulin sensitizer in type 2 diabetic patients and implicated in apoptosis, cell proliferation, and cell cycle regulation. Here, the effect of thiazolidinediones on G1-phase cell cycle arrest, the hallmark in diabetic nephropathy, was investigated. Eight-week-old male Otsuka Long-Evans Tokushima fatty rats were treated with pioglitazone (1 mg·kg body wt-1·day-1) until 50 weeks of age and compared with insulin treatment. Although similar HbA1c levels were observed in both groups, pioglitazone significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion compared with the insulin-treated group. In addition, pioglitazone significantly reduced the number of glomerular p27Kip1-positive cells. Because prominent expression of PPAR-γ was observed in podocytes in glomeruli and cultured cells, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mmol/l D-glucose supplemented with pioglitazone. Pioglitazone inhibited cell hypertrophy revealed by [3H]thymidine and [3H]proline incorporation, and pioglitazone reversed high glucose-induced G1-phase cell cycle arrest, i.e., an increase in G0/G1 phase and decrease in S and G2 phases. Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27Kip1 protein levels. Besides glucose-lowering action, pioglitazone ameliorates diabetic nephropathy via cell cycle-dependent mechanisms.

Original languageEnglish
Pages (from-to)1666-1677
Number of pages12
JournalDiabetes
Volume55
Issue number6
DOIs
Publication statusPublished - 2006

Fingerprint

pioglitazone
Thiazolidinediones
Diabetic Nephropathies
Cell Cycle
G1 Phase
G1 Phase Cell Cycle Checkpoints
Glucose
Podocytes
Peroxisome Proliferator-Activated Receptors
Insulin
Hypertrophy
Cultured Cells
Inbred OLETF Rats
Cyclin-Dependent Kinase Inhibitor p27
Cell Cycle Resting Phase
G2 Phase
Mitogen-Activated Protein Kinases
S Phase
Proline
Thymidine

Keywords

  • CDK, cyclin-dependent kinase
  • DMEM, Dulbecco's modified Eagle's medium
  • ERK, extracellular signal-regulated kinase
  • MAPK, mitogen-activated protein kinase
  • MPC, mouse podocyte cell
  • PAS, periodic acid-Schiff

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. / Okada, Tatsuo; Wada, Jun; Hida, Kazuyuki; Eguchi, Jun; Hashimoto, Izumi; Baba, Masako; Yasuhara, Akihiro; Shikata, Kenichi; Makino, Hirofumi.

In: Diabetes, Vol. 55, No. 6, 2006, p. 1666-1677.

Research output: Contribution to journalArticle

Okada, Tatsuo ; Wada, Jun ; Hida, Kazuyuki ; Eguchi, Jun ; Hashimoto, Izumi ; Baba, Masako ; Yasuhara, Akihiro ; Shikata, Kenichi ; Makino, Hirofumi. / Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. In: Diabetes. 2006 ; Vol. 55, No. 6. pp. 1666-1677.
@article{4e3aa8300d154510a585205f867a7515,
title = "Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms",
abstract = "Thiazolidinediones are ligands for peroxisome proliferator-activated receptor (PPAR)-γ, widely used as insulin sensitizer in type 2 diabetic patients and implicated in apoptosis, cell proliferation, and cell cycle regulation. Here, the effect of thiazolidinediones on G1-phase cell cycle arrest, the hallmark in diabetic nephropathy, was investigated. Eight-week-old male Otsuka Long-Evans Tokushima fatty rats were treated with pioglitazone (1 mg·kg body wt-1·day-1) until 50 weeks of age and compared with insulin treatment. Although similar HbA1c levels were observed in both groups, pioglitazone significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion compared with the insulin-treated group. In addition, pioglitazone significantly reduced the number of glomerular p27Kip1-positive cells. Because prominent expression of PPAR-γ was observed in podocytes in glomeruli and cultured cells, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mmol/l D-glucose supplemented with pioglitazone. Pioglitazone inhibited cell hypertrophy revealed by [3H]thymidine and [3H]proline incorporation, and pioglitazone reversed high glucose-induced G1-phase cell cycle arrest, i.e., an increase in G0/G1 phase and decrease in S and G2 phases. Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27Kip1 protein levels. Besides glucose-lowering action, pioglitazone ameliorates diabetic nephropathy via cell cycle-dependent mechanisms.",
keywords = "CDK, cyclin-dependent kinase, DMEM, Dulbecco's modified Eagle's medium, ERK, extracellular signal-regulated kinase, MAPK, mitogen-activated protein kinase, MPC, mouse podocyte cell, PAS, periodic acid-Schiff",
author = "Tatsuo Okada and Jun Wada and Kazuyuki Hida and Jun Eguchi and Izumi Hashimoto and Masako Baba and Akihiro Yasuhara and Kenichi Shikata and Hirofumi Makino",
year = "2006",
doi = "10.2337/db05-1285",
language = "English",
volume = "55",
pages = "1666--1677",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms

AU - Okada, Tatsuo

AU - Wada, Jun

AU - Hida, Kazuyuki

AU - Eguchi, Jun

AU - Hashimoto, Izumi

AU - Baba, Masako

AU - Yasuhara, Akihiro

AU - Shikata, Kenichi

AU - Makino, Hirofumi

PY - 2006

Y1 - 2006

N2 - Thiazolidinediones are ligands for peroxisome proliferator-activated receptor (PPAR)-γ, widely used as insulin sensitizer in type 2 diabetic patients and implicated in apoptosis, cell proliferation, and cell cycle regulation. Here, the effect of thiazolidinediones on G1-phase cell cycle arrest, the hallmark in diabetic nephropathy, was investigated. Eight-week-old male Otsuka Long-Evans Tokushima fatty rats were treated with pioglitazone (1 mg·kg body wt-1·day-1) until 50 weeks of age and compared with insulin treatment. Although similar HbA1c levels were observed in both groups, pioglitazone significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion compared with the insulin-treated group. In addition, pioglitazone significantly reduced the number of glomerular p27Kip1-positive cells. Because prominent expression of PPAR-γ was observed in podocytes in glomeruli and cultured cells, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mmol/l D-glucose supplemented with pioglitazone. Pioglitazone inhibited cell hypertrophy revealed by [3H]thymidine and [3H]proline incorporation, and pioglitazone reversed high glucose-induced G1-phase cell cycle arrest, i.e., an increase in G0/G1 phase and decrease in S and G2 phases. Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27Kip1 protein levels. Besides glucose-lowering action, pioglitazone ameliorates diabetic nephropathy via cell cycle-dependent mechanisms.

AB - Thiazolidinediones are ligands for peroxisome proliferator-activated receptor (PPAR)-γ, widely used as insulin sensitizer in type 2 diabetic patients and implicated in apoptosis, cell proliferation, and cell cycle regulation. Here, the effect of thiazolidinediones on G1-phase cell cycle arrest, the hallmark in diabetic nephropathy, was investigated. Eight-week-old male Otsuka Long-Evans Tokushima fatty rats were treated with pioglitazone (1 mg·kg body wt-1·day-1) until 50 weeks of age and compared with insulin treatment. Although similar HbA1c levels were observed in both groups, pioglitazone significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion compared with the insulin-treated group. In addition, pioglitazone significantly reduced the number of glomerular p27Kip1-positive cells. Because prominent expression of PPAR-γ was observed in podocytes in glomeruli and cultured cells, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mmol/l D-glucose supplemented with pioglitazone. Pioglitazone inhibited cell hypertrophy revealed by [3H]thymidine and [3H]proline incorporation, and pioglitazone reversed high glucose-induced G1-phase cell cycle arrest, i.e., an increase in G0/G1 phase and decrease in S and G2 phases. Pioglitazone suppressed high glucose-induced phosphorylation of p44/42 mitogen-activated protein kinase and reduced Bcl-2 and p27Kip1 protein levels. Besides glucose-lowering action, pioglitazone ameliorates diabetic nephropathy via cell cycle-dependent mechanisms.

KW - CDK, cyclin-dependent kinase

KW - DMEM, Dulbecco's modified Eagle's medium

KW - ERK, extracellular signal-regulated kinase

KW - MAPK, mitogen-activated protein kinase

KW - MPC, mouse podocyte cell

KW - PAS, periodic acid-Schiff

UR - http://www.scopus.com/inward/record.url?scp=33748335467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748335467&partnerID=8YFLogxK

U2 - 10.2337/db05-1285

DO - 10.2337/db05-1285

M3 - Article

VL - 55

SP - 1666

EP - 1677

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -